Next report date
Report period
Q1 2024
EPS estimate
−0.85USD
Revenue estimate
—
−98.79 MUSD
25.39 M
Om Relmada Therapeutics, Inc.
Sektor
Bransch
VD
Sergio Traversa
Webbplats
Huvudkvarter
Coral Gables
Employees (FY)
20
Grundat
2012
FIGI
BBG003MKSL16
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
